Literature DB >> 27069151

Predictors of Survival in Acute Myeloid Leukemia by Treatment Modality.

Samip Master1, Richard Mansour1, Srinivas S Devarakonda1, Zhenzhen Shi2, Glenn Mills1, Runhua Shi3.   

Abstract

BACKGROUND/AIM: Evaluations of efficacy of treatment modality in analyses on patients with acute myeloid leukemia (AML) often combine chemotherapy and stem cell transplantation (SCT). To account for the effect of SCT and determine the impact of chemotherapy alone, the National Cancer Data Base from 1998-2011 was analyzed. PATIENTS AND METHODS: Patients with AML from 1998-2011 aged 18-64 years were included. Chi-square analysis was used to assess the association between treatment and factors investigated. The Kaplan-Meier method was used to assess overall survival. Log-rank methods were used to determine factors significant for survival. Multivariable Cox regression analysis was used to determine the effect of chemotherapy alone, and both chemotherapy and SCT on survival while adjusting for other variables.
RESULTS: A total of 34,816 patients from the National Cancer Database were eligible for this study. Eighty-four percent of patients received chemotherapy alone, 8.3% no chemotherapy or SCT, and 7.5 % received both chemotherapy and SCT. Five-year survival for patients without chemotherapy without SCT was 12%, survival for the group treated with chemotherapy alone was 37.8% and for those receiving both chemotherapy and SCT was 44.1%. Treatment with chemotherapy only and chemotherapy plus SCT had a hazard ratio for death of 0.42 and 0.35 compared to no chemotherapy or SCT. Advanced age, male sex, Black race, diagnosis prior to 2004, multiple comorbidities, Medicare insurance, Medicaid insurance, no insurance, lower income and low education level, distance less than 30 miles from treatment Center, diagnosis and treatment at same facility, were independently associated with worse survival.
CONCLUSION: Survival analysis of AML in the National Cancer Database showed multiple factors to be independently associated with survival. Outcomes based on treatment suggest an improved survival when utilizing chemotherapy and SCT as the primary treatment modality. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  AML; Acute myeloid leukemia; chemotherapy; survival; transplant

Mesh:

Substances:

Year:  2016        PMID: 27069151

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Impact of race on outcomes in intermediate-risk acute myeloid leukemia.

Authors:  Ivy Elizabeth Abraham; Anand Ashwin Patel; Heidy Wang; John Patrick Galvin; Olga Frankfurt; Li Liu; Irum Khan
Journal:  Cancer Causes Control       Date:  2021-04-09       Impact factor: 2.506

2.  Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set.

Authors:  G Goyal; A C Bartley; M M Patnaik; M R Litzow; A Al-Kali; R S Go
Journal:  Blood Cancer J       Date:  2017-08-25       Impact factor: 11.037

3.  Long-term cardiac-specific mortality among 44,292 acute myeloid leukemia patients treated with chemotherapy: a population-based analysis.

Authors:  Guangli Li; Zhijuan Zhou; Wencong Yang; Hao Yang; Xiuwu Fan; Yuelan Yin; Liyun Luo; Jinyou Zhang; Niujian Wu; Zibin Liang; Jianting Ke; Jian Chen
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207

4.  Distance to treatment center is associated with survival in children and young adults with acute lymphoblastic leukemia.

Authors:  Seth J Rotz; Wei Wei; Stefanie M Thomas; Rabi Hanna
Journal:  Cancer       Date:  2020-09-10       Impact factor: 6.860

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.